*Disclaimer

PROTEOMICS INTERNATIONAL LABORATORIES LTD (ASX: PIQ)

🔗 📄 📈

PIQ: Sonic Healthcare USA signs licence for PromarkerD in the US

PROTEOMICS INTERNATIONAL LABORATORIES LTD

2023-05-10 11:41:00

PIQ: World Endometriosis Congress - New diagnostic test showcased

PROTEOMICS INTERNATIONAL LABORATORIES LTD

2023-05-05 08:15:00

PIQ: Canagliflozin lowers PromarkerD DKD risk prediction scores

PROTEOMICS INTERNATIONAL LABORATORIES LTD

2023-05-03 08:15:00

PIQ: Proteomics renews ISO 13485 and ISO 17025 accreditations

PROTEOMICS INTERNATIONAL LABORATORIES LTD

2023-04-17 08:21:00

PIQ: New endometriosis test presented at international conference

PROTEOMICS INTERNATIONAL LABORATORIES LTD

2023-03-24 17:39:00

PIQ: PromarkerD application for Australian MBS to be resubmitted

PROTEOMICS INTERNATIONAL LABORATORIES LTD

2023-03-15 15:05:00

PIQ: Distribution agreement for PromarkerD in Britain extended

PROTEOMICS INTERNATIONAL LABORATORIES LTD

2023-02-15 08:01:00

PIQ: Letter of intent with Sonic Healthcare USA extended

PROTEOMICS INTERNATIONAL LABORATORIES LTD

2023-01-31 09:19:00

PIQ: Letter of intent with Sonic Healthcare USA extended

PROTEOMICS INTERNATIONAL LABORATORIES LTD

  1. Proteomics International Laboratories Ltd (PIQ) has extended the term of its letter of intent with Sonic Healthcare USA, Inc. (a division of Sonic Healthcare Limited; ASX: SHL) until 31st January 2023.
  2. The binding and exclusive LOI, initially signed in August, provides for entering into an Exclusive Licence Agreement for use of Proteomics International's PromarkerD predictive test for diabetic kidney disease in the United States by Sonic Healthcare USA.
  3. A number of key milestones have already been achieved under the LOI, including PromarkerD becoming a featured test on the Sonic Reference Lab test menu in October.

2023-01-05 08:16:00

PIQ: CPT PLA reimbursement code approved in US for PromarkerD

PROTEOMICS INTERNATIONAL LABORATORIES LTD

  1. American Medical Association (AMA) approves US reimbursement code (CPT® Proprietary Laboratory Analyses [PLA] code) for PromarkerD test for diabetic kidney disease
  2. Securing a new dedicated CPT PLA code is a major milestone and key to reimbursement coverage of the test by both Medicare and private health insurers in the US
  3. Approximately 32 million adults, or 11 per cent of the population, are living with diabetes in the United States

2023-01-03 08:23:00